Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Western Asia is experiencing significant growth due to several factors.
Customer preferences: Patients in Western Asia are increasingly seeking out anti-coagulant treatments due to the rising incidence of cardiovascular diseases, which are a leading cause of death in the region. Additionally, an aging population is driving demand for these treatments as older individuals are more likely to suffer from conditions that require anti-coagulants.
Trends in the market: The market for anti-coagulants in Western Asia is growing at a rapid pace due to the increasing demand for these treatments. One trend that is driving this growth is the rise of novel oral anti-coagulants (NOACs), which are more effective and easier to administer than traditional anti-coagulants. Additionally, there is a growing preference for NOACs over warfarin due to their lower risk of bleeding and fewer drug interactions.
Local special circumstances: One factor that is contributing to the growth of the anti-coagulants market in Western Asia is the high prevalence of risk factors for cardiovascular disease in the region. These risk factors include smoking, obesity, and diabetes, all of which are more common in Western Asia than in other parts of the world. Additionally, the region has a high incidence of stroke, which is a major indication for anti-coagulant treatment.
Underlying macroeconomic factors: The growth of the anti-coagulants market in Western Asia is also being driven by broader macroeconomic trends in the region. These include rising disposable incomes, which are enabling more patients to access expensive treatments, as well as increasing investment in healthcare infrastructure. Additionally, the region has a large and growing population, which is creating a large market for healthcare products and services.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
